|The risk of stent thrombosis in patients with acute coronary syndromes treated with bare-metal and drug-eluting stents.|
|PMID: 19539258 Owner: NLM Status: MEDLINE|
|OBJECTIVES: We aimed to evaluate the risk of definite stent thrombosis with bare-metal stents (BMS) and drug-eluting stents (DES) in patients treated for acute coronary syndromes.
BACKGROUND: Acute coronary syndromes (ACS) have been reported as increasing the risk for stent thrombosis.
METHODS: Between January 2000 and December 2005, 5,816 consecutive patients underwent percutaneous coronary intervention for de novo lesions with a single stent type. These patients consisted of 3 sequential groups of BMS (n = 2,248), sirolimus-eluting stents (n = 822) and paclitaxel-eluting stents (n = 2,746). In total, 3,485 patients presented with an ACS.
RESULTS: After a median follow-up of 1,394 days, patients with ACS had a definite stent thrombosis rate of 2.5% versus 1.0% in patients with stable angina (propensity score-adjusted hazard ratio [HR]: 2.80, 95% confidence interval [CI]: 1.72 to 4.56). ACS patients had a higher risk of early and late stent thrombosis, although the increased risk of very late stent thrombosis was only present in ACS patients treated with DES. In stable patients, any stent thrombosis resulted in a significant increase in mortality (adjusted HR: 4.0, 95% CI: 1.7 to 9.3), although this was particularly evident for late or very late stent thrombosis; in contrast only early stent thrombosis significantly increased mortality in patients with acute coronary syndrome patients (adjusted HR: 2.0, 95% CI: 1.0 to 4.1).
CONCLUSIONS: Patients with acute coronary syndromes are at higher risk of early and late stent thrombosis with either BMS or DES, although very late stent thrombosis seems to be uniquely associated with DES. The clinical sequelae of late and very late stent thrombosis are more pronounced in stable patients.
|Neville Kukreja; Yoshinobu Onuma; Hector M Garcia-Garcia; Joost Daemen; Ron van Domburg; Patrick W Serruys;|
Related Documents :
|12050298 - New eptfe/fep-covered stent in the palliative treatment of malignant biliary obstruction.
20074158 - Successful stenting in ductal disruption favorably impacts treatment outcomes in patien...
9831268 - Expandable stents compared to conventional plastic endoprostheses in malignant oesophag...
19136108 - Metallic stents for gastric outlet obstruction: reintervention rate is lower with uncov...
20347688 - Changes in health-related quality of life after ultrasound-guided foam sclerotherapy fo...
12131738 - Does reconstruction of posterior ligamentous complex with extensor musculature decrease...
|Type: Comparative Study; Journal Article|
|Title: JACC. Cardiovascular interventions Volume: 2 ISSN: 1876-7605 ISO Abbreviation: JACC Cardiovasc Interv Publication Date: 2009 Jun|
|Created Date: 2009-06-22 Completed Date: 2009-08-27 Revised Date: 2014-09-05|
Medline Journal Info:
|Nlm Unique ID: 101467004 Medline TA: JACC Cardiovasc Interv Country: United States|
|Languages: eng Pagination: 534-41 Citation Subset: IM|
|APA/MLA Format Download EndNote Download BibTex|
Acute Coronary Syndrome
Angina Pectoris / complications, mortality, therapy*
Angioplasty, Balloon, Coronary / adverse effects*, instrumentation*, mortality
Cardiovascular Agents / administration & dosage
Paclitaxel / administration & dosage
Proportional Hazards Models
Sirolimus / administration & dosage
Thrombosis / etiology*, mortality
|0/Cardiovascular Agents; 0/Metals; 33069-62-4/Paclitaxel; W36ZG6FT64/Sirolimus|
|P J de Feyter / ; P P T de Jaegere / ; H J Duckers / ; S H Hofma / ; E McFadden / ; E Regar / ; G Sianos / ; P C Smits / ; M J van der Ent / ; W J van der Giessen / ; C A van Mieghem /|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: A prospective, multicenter, randomized trial to assess efficacy of pioglitazone on in-stent neointim...
Next Document: Characterization of post-operative risk associated with prior drug-eluting stent use.